Abstracts Archive - Page 1447 of 2425 - ACR Meeting Abstracts

Abstract Number: 436 • 2016 ACR/ARHP Annual Meeting
Are Providers Recommending Appropriate Screening for Hydroxychloroquine-Induced Retinal Toxicity to Their Patients?
Sarah Haserodt¹, Chris Tonner², Gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Internal Medicine, California Pacific Medical Center, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Although well tolerated by most patients, hydroxychloroquine (HCQ) can cause irreversible retinal damage. The American Association of Ophthalmology (AAO) 2016 Guidelines recommend a baseline…
Abstract Number: 437 • 2016 ACR/ARHP Annual Meeting
Incidence of Gastrointestinal Events and Physician Compliance of Co-Prescribing Proton Pump Inhibitors in Chronic NSAID Users with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis
Arina Garg, Rakeeba Din, Daniel Torres Leyva, Maryam Hasan, Ma Moe and Bruce Garner, NYU Lutheran Medical Center, Brooklyn, NY
Background/Purpose: The most common group of patients with chronic use of NSAIDs include those with rheumatic diseases such as osteoarthritis (OA), rheumatoid arthritis (RA) and…
Abstract Number: 438 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Adverse Effects – the Patient Perspective
Rachel Black¹, Susan M. Goodman², Carlee Ruediger³, Susan Lester⁴, Sarah Mackie⁵ and Catherine Hill³, ¹Department of Medicine, The University of Adelaide, Adelaide, Australia, ²Medicine, Hospital for Special Surgery, New York, NY, ³Medicine, The University of Adelaide, Adelaide, Australia, ⁴Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom
Background/Purpose: Glucocorticoid (GC) use and adverse effects (AEs) are prevalent in rheumatic diseases, yet there is no standardized patient-reported outcome measure to assess benefit and…
Abstract Number: 439 • 2016 ACR/ARHP Annual Meeting
Temple University Hospital Rheumatology Narcotic Contract
Alexis Zavitsanos¹, King Goh², Shikha Rathi³, Alice Livshits³ and Irene Tan³, ¹Rheumatology, Temple University Hospital, Philadelphia, PA, ²Rheumatology, Temple University, Philadelphia, PA, ³Temple University Hospital, Philadelphia, PA
Background/Purpose: The use of opioids in treating chronic pain can be difficult and is a common problem across multiple specialties, including rheumatology. Opioid contracts have…
Abstract Number: 440 • 2016 ACR/ARHP Annual Meeting
the Majority of Biologic Injectors Are Stored Under Suboptimal Conditions at Home
Marin de Jong¹, Marieke Pierik¹, Andy Peters¹, Mark Roemers², Veronique Hilhorst³ and A. van Tubergen⁴, ¹Department of Internal Medicine, division of Gastroenterology, Maastricht University Medical Centre, Maastricht, Netherlands, ²AntTail, Utrecht, Netherlands, ³Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre, m, Netherlands, ⁴Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: The introduction of biologics has significantly improved long-term outcome of immune-mediated inflammatory diseases. However, after discontinuation or switch of therapy, 26-49% of patients on…
Abstract Number: 441 • 2016 ACR/ARHP Annual Meeting
Improving Care and Avoiding Errors. Can Our Patients Recall Their Medications and Create an Accurate Medication List?
Carla F Gamarra-Hilburn and Salvador Vila, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: Medications errors are common and are an important cause of morbidity and mortality. We aimed to evaluate patient accuracy in recalling current medication use,…
Abstract Number: 442 • 2016 ACR/ARHP Annual Meeting
Comparison of Adherence and Dosing Interval of Subcutaneous Anti-TNF Biologics in Inflammatory Arthritis from a Canadian Administrative Database.
Peter Bhoi¹, Louis Bessette², Mary Bell³, Cathy Tkaczyk⁴, Francois Nantel⁵ and Karina Maslova¹, ¹Janssen Inc., Toronto, ON, Canada, ²Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁵19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Subcutaneous (SC) anti-TNF agents such as Golimumab (GLM) Adalimumab (ADA), Etanercept (ETA) and Certolizumab pegol (CZP) Index period was from January 1, 2010 -…
Abstract Number: 443 • 2016 ACR/ARHP Annual Meeting
Repetitive Requisition of Antinuclear Antibody Testing (ANA) in Outpatient Multispecialty Clinics in Patients with a Known Positive ANA
Laura Amorese-O'Connell¹, Pinky Vaidya², Durkhani Mahboob², Charis Gn³ and Stuart Schwartz⁴, ¹Rheumatology, Brown University, RI hospital, Providence, RI, ²Rheumatology, Roger Williams Medical Center, Providence, RI, ³Internal Medicine, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, ⁴Brown Medical School, Providence, RI
Background/Purpose: Methods: Retrospective chart review was performed on 598 patients who underwent ANA testing between April 1st, 2015 and March 31st, 2016. Data collected…
Abstract Number: 444 • 2016 ACR/ARHP Annual Meeting
Improvement in Knee Arthrocentesis Via Constant Compression
Tej Bhavsar¹, Wilmer Sibbitt Jr.¹, Romy Cabacungan¹, Timothy Moore¹, Luis Salayandia¹, Roderick Fields², Arthur Bankhurst³, Suzanne Emil¹, Monthida Fangtham¹ and Konstantin Konstantinov⁴, ¹Rheumatology, University of New Mexico, Albuquerque, NM, ²Internal Medicine/ Rheumatology, University of New Mexico School of Medicine, Albuquerque, NM, ³Rheumatology, University of NM Medical Center, Albuquerque, NM, ⁴1 University Of New Mexico, University of New Mexico, Albuquerque, NM
Background/Purpose: Arthrocentesis has emerged as a highly valuable diagnostic and therapeutic intervention for rheumatic diseases since first standardized by Hollander in the 1950’s. Successful arthrocentesis…
Abstract Number: 445 • 2016 ACR/ARHP Annual Meeting
Performance of Promis Measures in a Multi-Ethnic Population-Based Systemic Lupus Erythematosus (SLE) Cohort
Patricia P. Katz¹, Jinoos Yazdany¹, Laura Trupin¹, Stephanie Rush², Cristina Lanata³, Charles G. Helmick⁴, Lindsey A. Criswell³ and Maria Dall'Era⁵, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²UCSF, SF, CA, ³Division of Rheumatology, UCSF, San Francisco, CA, ⁴CDC, Atlanta, GA, ⁵Division of Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: NIH’s PROMIS (Patient-Reported Outcomes Measurement Information System) measures have the potential to improve and expand outcomes measurement in SLE, but have not been tested…
Abstract Number: 446 • 2016 ACR/ARHP Annual Meeting
A Multi-Group Confirmatory Factor Analyses of the Lupuspro Between Southern California and Filipino Samples of Patients with SLE
Desiree Azizoddin¹, R. Olmstead², Chelsie Cost³, Geraldine Zamora Racaza⁴, Julia Ayeroff⁵, Lekeisha Sumner⁶, Michael Weisman⁷, Perry M. Nicassio⁸ and Meenakshi Jolly⁹, ¹Department of Psychology, Loma Linda University, Loma Linda, CA, ²UCLA, Los Angeles, CA, ³Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Postbaccalaureate Premedical Program, University of Southern California, Los Angeles, CA, CA, ⁶Department of Psychology, Cedars Sinai Medical Center, Los Angeles, CA, ⁷Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Cousins Center for PNI, UCLA, LA, CA, ⁹Rush, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) leads to a variety of health outcomes through complex disease paths. The LupusPro (LP) is a comprehensive self-report measure which…
Abstract Number: 447 • 2016 ACR/ARHP Annual Meeting
The Influence of Risk Presentation Format on Willingness to Start a Medication
Raluca Cozmuta¹, Evan Wilhelms², Valerie Reyna³, Julia Nolte³ and Liana Fraenkel⁴, ¹Emory University School of Medicine, Atlanta, GA, ²Vasser College, Poughkeepsie, NY, ³Cornell University, Ithica, NY, ⁴Yale University School of Medicine, New Haven, CT
Background/Purpose: Patients with rheumatoid arthritis frequently refuse to escalate care because they overweight the probability of adverse events. Effectively communicating risk information to patients is…
Abstract Number: 448 • 2016 ACR/ARHP Annual Meeting
Cross-Cultural and Construct Validity of the Animated Activity Questionnaire to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis in Different Languages
Wilfred Peter¹, Henrica de Vet², Maarten Boers³, Jaap Harlaar⁴, Leo D. Roorda⁵, Rudolf Poolman⁶, Vanessa Scholtes⁷, Martijn P.M. Steultjens⁸, Gordon Hendry⁹, Ewa M. Roos¹⁰, Francis Guillemin¹¹, Maria Grazia Benedetti¹², Lorenzo Cavazutti¹², Antonio Escobar Martinez¹³, Hanne Dagfinrud¹⁴ and Caroline Terwee¹⁵, ¹Department of Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, Netherlands, ²EMGO Institute, VU Medical Centre, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, VU Univ Medical Center F-wing, Amsterdam, Netherlands, ⁴Dep of Rehabilitation Medicine and MOVE research institute, VU University Medical Center, Amsterdam, Netherlands, ⁵Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁶Orthopedic department, Joint Reserach, OLVG, Amsterdam, Netherlands, ⁷Department of Orthopedics, Joint Research, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands, ⁸Rehabilitation Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁹School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, United Kingdom, ¹⁰Inst Sports and Biomechanics, University of Southern Denmark, Odense, Denmark, ¹¹University of Lorraine, Nancy, France, ¹²Physical Medicine and Rehabilitation Unit, Istituto Ortopedico Rizzoli, Bologna, Italy, ¹³Health Service Research Network on Chronic Diseases (REDISSEC), Basurto University Hospital, Bilbao, Spain, ¹⁴Department of Rheumatology /National Advosory Unit for Rehabilitation in Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁵Dep of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Application of the AAQ in international studies requires good cross-cultural validity, i.e. minimal Differential Item Functioning (DIF) across countries. The aim of this study…
Abstract Number: 449 • 2016 ACR/ARHP Annual Meeting
the Animated Activity Questionnaire to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis: Reliability, Responsiveness, and Interpretation
Wilfred Peter¹, Henrica de Vet², Rudolf Poolman³, Vanessa Scholtes⁴, Dionne Timmermans⁵, Nina Klein Essink⁵ and Caroline Terwee⁶, ¹Amsterdam Rehabilitation Research Centre, Reade, centre for rehabilitation and rheumatology, Amsterdam, Netherlands, ²EMGO Institute, VU Medical Centre, Amsterdam, Netherlands, ³Orthopedic department, Joint Reserach, OLVG, Amsterdam, Netherlands, ⁴Department of Orthopedics, Joint Research, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands, ⁵Orthopedics, Joint Research, OLVG, Amsterdam, Netherlands, ⁶Dep of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: A newly developed and (cross-cultural) validated measurement tool, the computerized Animated Activity Questionnaire (AAQ) for assessing activity limitations in hip and knee osteoarthritis (HKOA)…
Abstract Number: 450 • 2016 ACR/ARHP Annual Meeting
Coming Full Circle with the Omeract RA Flare Questionnaire (RA-FQ): Further Evaluation of the Properties, Meaningfulness, and Utility through Rasch Analysis and Feedback from RA Patients
Susan J. Bartlett^1,2, Skye Barbic³, Vivian P. Bykerk⁴, Bruno Fautrel⁵, Francis Guillemin⁶, A den Broeder⁷, R Alten⁸, Robin Christensen⁹, Ernest H. Choy¹⁰, Daniel E. Furst¹¹, Sarah Hewlett¹², Amye L. Leong¹³, Lyn March¹⁴, Thasia G Woodworth¹⁵, Clifton Bingham III¹⁶ and OMERACT Flare Group and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of British Columbia, Vancouver, BC, Canada, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁶University of Lorraine, Nancy, France, ⁷Rheumatology, Maartenskliniek, Nijmegen, Netherlands, ⁸Schlosspark-Klinik University Medicine, Berlin, Germany, ⁹The Parker instutute, RC, Copenhagen, Denmark, ¹⁰Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ¹¹University of California, Los Angeles, Los Angeles, CA, ¹²Academic Rheumatology, University of West of England, Bristol, United Kingdom, ¹³Spokesperson; Strategic Relations, BONE AND JOINT DECADE, Santa Barbara, CA, ¹⁴Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹⁵Leading Edge Clinical Research, Stuart, FL, ¹⁶Johns Hopkins University, Baltimore, MD
Background/Purpose: OMERACT Filter 2.0 encourages use of robust methods to develop new measures. Instrument results also should be highly relevant, easily scored and interpreted, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].